P
PT Etana Biotechnologies Indonesia
Engaged in manufacturing, R&D and marketing of recombinant gene-technology, monoclonal antibody (MAB’s) drugs and vaccines
About PT Etana Biotechnologies Indonesia
Established in 2014 by founder Nathan Tirtana, PT Etana Biotechnologies Indonesia (Etana) is a biopharmaceutical company focused on developing and commercializing biologic drugs for the Southeast Asian market. The company operates in research, development, manufacturing, and marketing of therapies for oncology, autoimmune disorders, metabolic diseases, and other life-threatening conditions. Etana's business model centers on making treatments more accessible and affordable through local production, aligning with Indonesian government health programs.
Etana has positioned itself in the region by becoming the first pharmaceutical entity in ASEAN with mRNA technology capabilities. This platform allows for rapid development of new vaccines and other biopharmaceutical products. A significant milestone was the inauguration of its biopharmaceutical factory in the Pulogadung Industrial Estate, East Jakarta, in October 2022, an event attended by the President of the Republic of Indonesia. This facility adheres to international Good Manufacturing Practices (cGMP) and has received halal certification, enabling the production of a wide range of biologic therapies. The company has received multiple rounds of funding from international investors, including DEG, Yunfeng Capital, HighLight Capital, and East Ventures, to expand its product pipeline and manufacturing capacity, particularly in oncology.
The company's product portfolio includes treatments for oncology, nephrology, vaccines, and metabolic conditions. Key products include a bevacizumab biosimilar (BEVAGEN), used for treating advanced non-small cell lung cancer and metastatic colorectal cancer, produced under license from Innovent Biologics. Etana also produces Erythropoietin (EPO), marketed as RENOGEN, for anemia associated with chronic kidney disease. In response to the global pandemic, Etana developed an mRNA COVID-19 vaccine, InaRNAVac, through a technology transfer collaboration with Chinese firms, which received an Emergency Use Authorization from Indonesia's food and drug authority (BPOM) and halal certification. The company is also expanding into other vaccine platforms, including adenovirus technology and a PCV-13 vaccine for pneumonia in children. Its strategic collaborations with international pharmaceutical companies and local academic institutions, such as Universitas Gadjah Mada (UGM), are central to its strategy of accelerating product development through technology transfer and joint research.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2025 | $30M | $120M | International Finance Corporation | ↗ |
| LATE VCOther financing | Mar 2023 | — | — | Highlight Capital · German Investment Corporation · East Ventures · YunFeng Capital | ↗ |
Growth signals
Latest recorded traffic for PT Etana Biotechnologies Indonesia is 5.1K monthly website visits, up 41.7% over the last three months. PT Etana Biotechnologies Indonesia's team grew 8.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PT Etana Biotechnologies Indonesia in its local ecosystem
The PT Etana Biotechnologies Indonesia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
YunFeng Capital
Series B and later5 investors entered at this stage
Legend Capital
German Investment Corporation
Highlight Capital
East Ventures
International Finance Corporation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PT Etana Biotechnologies Indonesia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PT Etana Biotechnologies Indonesia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







